Compare · ARAY vs MDLN
ARAY vs MDLN
Side-by-side comparison of Accuray Incorporated (ARAY) and Medline Inc. (MDLN): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ARAY and MDLN operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- MDLN is the larger of the two at $44.15B, about 1085.5x ARAY ($40.7M).
- Over the past year, ARAY is down 73.6% and MDLN is down 19.0% - MDLN leads by 54.7 points.
- MDLN has been more active in the news (20 items in the past 4 weeks vs 7 for ARAY).
- MDLN has more recent analyst coverage (25 ratings vs 4 for ARAY).
- Company
- Accuray Incorporated
- Medline Inc.
- Price
- $0.34-0.80%
- $33.02-1.74%
- Market cap
- $40.7M
- $44.15B
- 1M return
- +14.12%
- -21.39%
- 1Y return
- -73.62%
- -18.96%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2007
- 2025
- News (4w)
- 7
- 20
- Recent ratings
- 4
- 25
Accuray Incorporated
Accuray Incorporated designs, develops, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the body in the Americas, Europe, the Middle East, India, Japan, Africa, and rest of the Asia Pacific region. The company offers the CyberKnife System, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of various types of cancer and tumors in the body. Its CyberKnife System automatically tracks, detects, and corrects for tumor and patient movement in real-time during the procedure, as well as enables the delivery of precise, high dose radiation while patients breathe normally. The company also offers the TomoTherapy System, including the Radixact System, which consists of an integrated and versatile radiation therapy system used for the treatment of a range of cancer types. It markets its products in the United States directly, as well as through sales organizations, sales agents, and group purchasing organizations; and directly, as well as through distributors and sales agents in Europe, Asia, and South America to hospitals and stand-alone treatment facilities. The company was incorporated in 1990 and is headquartered in Sunnyvale, California.
Latest ARAY
- Accuray Incorporated filed SEC Form 8-K: Termination of a Material Definitive Agreement, Regulation FD Disclosure
- SEC Form 4 filed by SVP, Chief Commercial Officer Miele Paul Michael
- SEC Form SD filed by Accuray Incorporated
- Accuray Incorporated Reports Inducement Award Under NASDAQ Listing Rules
- SEC Form S-8 filed by Accuray Incorporated
- Amendment: SEC Form SCHEDULE 13D/A filed by Accuray Incorporated
- SEC Form 4 filed by Large owner Tcw Group Inc
- Accuray and the University of Wisconsin-Madison Announce Master Research Agreement to Improve Personalized Care for Patients with Cancer
- Accuray downgraded by BTIG Research
- SEC Form 10-Q filed by Accuray Incorporated
Latest MDLN
- Medline Inc. filed SEC Form 8-K: Creation of a Direct Financial Obligation, Entry into a Material Definitive Agreement
- Large owner Hellman & Friedman Capital Partners X (Parallel), L.P. sold $1,164,385,709 worth of shares (31,868,237 units at $36.54) and disposed of 1,887,801 shares (SEC Form 4)
- Director Healy Patrick J acquired 202,106 shares, increasing direct ownership by 15% to 1,387,921 units (SEC Form 4)
- Large owner Bx Mozart Ml-2 Holdco L.P. sold $1,217,349,994 worth of shares (33,317,824 units at $36.54) and disposed of 438,214 shares (SEC Form 4)
- Large owner Bcp 8 Holdings Mozart Manager L.L.C. sold $1,217,349,994 worth of shares (33,317,824 units at $36.54) and disposed of 438,214 shares (SEC Form 4)
- Medline's Prime Vendor model expands outside the United States
- Medline Inc. announces closing of upsized secondary offering of Class A common stock
- Medline announces participation in upcoming investor conferences
- MediWound Reports First Quarter 2026 Financial Results and Provides Corporate Update
- Large owner Bx Mozart Ml-1 Holdco L.P. converted options into 11,348,698 shares and disposed of 11,348,698 units of Class B Common Stock (SEC Form 4)